Global Collaboration Between CSL and Alentis to Develop and Commercialize Lixudebart for Treating Rare Kidney and Liver Diseases
October 6, 2026 — 04:25 CST
This Data Is Locked!
This area is available only to Subscribers.
CSL and Alentis have announced a global partnership to collaborate on the development and commercialization of Lixudebart, a treatment for rare kidney and liver diseases.... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
